Suzhou Huyun New Drug Research and Development Joint-stock Co., Ltd. is an innovation-driven small-molecule new drug R&D enterprise engaged in drug discovery and development based on natural products (NEEQ securities abbreviation: Suzhou Huyun; securities code: 833464). Huyun has consistently adhered to an independent innovation development strategy, focusing on disease areas with relatively complex pathogenesis such as cardiovascular and cerebrovascular diseases and autoimmune diseases, exploring traditional medicinal plant resources, analyzing their natural product components, and establishing the connections between specific natural products and specific diseases.
Huyun focuses on disease areas with unmet clinical needs such as cardiovascular and cerebrovascular diseases (e.g., stroke, heart failure) and autoimmune diseases (e.g., psoriasis, inflammatory bowel disease). Huyun currently has 5 core R&D pipelines, of which 4 have entered the clinical stage: 1 is conducting Phase III clinical trials, 1 is preparing for Phase II clinical trials, 1 is in Phase I clinical trials, and 1 has received IND approval and is preparing for Phase I clinical trials.
What does Suzhou Huyun New Drug Research and Development Joint-stock Co., Ltd. require? Who is Suzhou Huyun hiring? Suzhou Huyun recruitment: 生物/制药/化工/环保类占比最多占82.4%,其次是其他(研发和技术类)占70.6%. What education can get in at Suzhou Huyun? 硕士占比最多占76.5%,其次是本科占23.5%. High education required at Suzhou Huyun? 硕士占76.5%. Work experience required at Suzhou Huyun? 1-3年占比最多占58.8%,其次是不限占17.6%. Where are the job locations at Suzhou Huyun? 苏州占比最多占100%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows